148 related articles for article (PubMed ID: 23159484)
1. Quinolines: a new hope against inflammation.
Mukherjee S; Pal M
Drug Discov Today; 2013 Apr; 18(7-8):389-98. PubMed ID: 23159484
[TBL] [Abstract][Full Text] [Related]
2. Medicinal chemistry of quinolines as emerging anti-inflammatory agents: an overview.
Mukherjee S; Pal M
Curr Med Chem; 2013; 20(35):4386-410. PubMed ID: 23862618
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists.
Blum CA; Caldwell T; Zheng X; Bakthavatchalam R; Capitosti S; Brielmann H; De Lombaert S; Kershaw MT; Matson D; Krause JE; Cortright D; Crandall M; Martin WJ; Murphy BA; Boyce S; Jones AB; Mason G; Rycroft W; Perrett H; Conley R; Burnaby-Davies N; Chenard BL; Hodgetts KJ
J Med Chem; 2010 Apr; 53(8):3330-48. PubMed ID: 20307063
[TBL] [Abstract][Full Text] [Related]
4. Novel acid-type cyclooxygenase-2 inhibitors: Design, synthesis, and structure-activity relationship for anti-inflammatory drug.
Hayashi S; Ueno N; Murase A; Nakagawa Y; Takada J
Eur J Med Chem; 2012 Apr; 50():179-95. PubMed ID: 22373734
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of new 4-carboxyl quinoline derivatives as cyclooxygenase-2 inhibitors.
Zarghi A; Ghodsi R; Azizi E; Daraie B; Hedayati M; Dadrass OG
Bioorg Med Chem; 2009 Jul; 17(14):5312-7. PubMed ID: 19560931
[TBL] [Abstract][Full Text] [Related]
6. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.
García-Martínez C; Fernández-Carvajal A; Valenzuela B; Gomis A; Van Den Nest W; Ferroni S; Carreño C; Belmonte C; Ferrer-Montiel A
J Pain; 2006 Oct; 7(10):735-46. PubMed ID: 17018334
[TBL] [Abstract][Full Text] [Related]
7. Effects of compounds from bi-qi capsule on the expression of inflammatory mediators in lipopolysaccharide-stimulated RAW 264.7 macrophages.
Wang QS; Cui YL; Wang YF; Chi W
J Ethnopharmacol; 2011 Jul; 136(3):480-7. PubMed ID: 20558268
[TBL] [Abstract][Full Text] [Related]
8. Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases.
Lim KM; Park YH
Arch Pharm Res; 2012 Mar; 35(3):393-6. PubMed ID: 22477184
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of new 2,3-diarylquinoline derivatives as selective cyclooxygenase-2 inhibitors.
Ghodsi R; Zarghi A; Daraei B; Hedayati M
Bioorg Med Chem; 2010 Feb; 18(3):1029-33. PubMed ID: 20061161
[TBL] [Abstract][Full Text] [Related]
10. Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
Smith VB; Spina D
Curr Opin Investig Drugs; 2005 Nov; 6(11):1136-41. PubMed ID: 16312135
[TBL] [Abstract][Full Text] [Related]
11. Local anti-inflammatory effect and behavioral studies on new PDE4 inhibitors.
Pieretti S; Dominici L; Di Giannuario A; Cesari N; Dal Piaz V
Life Sci; 2006 Jul; 79(8):791-800. PubMed ID: 16546218
[TBL] [Abstract][Full Text] [Related]
12. Dopamides, vanillylamides, ethanolamides, and arachidonic acid amides of anti-inflammatory and analgesic drug substances as TRPV1 ligands.
Sinning C; Watzer B; De Petrocellis L; Di Marzo V; Imming P
ChemMedChem; 2008 Dec; 3(12):1956-64. PubMed ID: 19003845
[TBL] [Abstract][Full Text] [Related]
13. Transient receptor potential vanilloid 1 channels modulate the synaptic effects of TNF-α and of IL-1β in experimental autoimmune encephalomyelitis.
Musumeci G; Grasselli G; Rossi S; De Chiara V; Musella A; Motta C; Studer V; Bernardi G; Haji N; Sepman H; Fresegna D; Maccarrone M; Mandolesi G; Centonze D
Neurobiol Dis; 2011 Sep; 43(3):669-77. PubMed ID: 21672630
[TBL] [Abstract][Full Text] [Related]
14. Discovery of oxazole-based PDE4 inhibitors with picomolar potency.
Kuang R; Shue HJ; Xiao L; Blythin DJ; Shih NY; Chen X; Gu D; Schwerdt J; Lin L; Ting PC; Cao J; Aslanian R; Piwinski JJ; Prelusky D; Wu P; Zhang J; Zhang X; Celly CS; Billah M; Wang P
Bioorg Med Chem Lett; 2012 Apr; 22(7):2594-7. PubMed ID: 22401864
[TBL] [Abstract][Full Text] [Related]
15. The search for new COX-2 inhibitors: a review of 2002 - 2008 patents.
Ramalho TC; Rocha M; da Cunha EF; Freitas MP
Expert Opin Ther Pat; 2009 Sep; 19(9):1193-228. PubMed ID: 19563267
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 inhibitors: promise or peril?
Mengle-Gaw LJ; Schwartz BD
Mediators Inflamm; 2002 Oct; 11(5):275-86. PubMed ID: 12467519
[TBL] [Abstract][Full Text] [Related]
17. The paradoxical role of the transient receptor potential vanilloid 1 receptor in inflammation.
Alawi K; Keeble J
Pharmacol Ther; 2010 Feb; 125(2):181-95. PubMed ID: 19896501
[TBL] [Abstract][Full Text] [Related]
18. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
[TBL] [Abstract][Full Text] [Related]
19. Transient receptor potential vanilloid 1 agonists as candidates for anti-inflammatory and immunomodulatory agents.
Tsuji F; Murai M; Oki K; Seki I; Ueda K; Inoue H; Nagelkerken L; Sasano M; Aono H
Eur J Pharmacol; 2010 Feb; 627(1-3):332-9. PubMed ID: 19878665
[TBL] [Abstract][Full Text] [Related]
20. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
